Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Conte, P; Ciruelos, E; Curigliano, G; De Laurentiis, M; Del Mastro, L; Gennari, A; Llombart, A; Martìn, M; Poggio, F; Prat, A; Puglisi, F; Saura, C.

" Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper" "

BREAST. 2024; 76: Nº de citas: 4 [doi:10.1016/j.breast.2024.103742]

Curigliano, G; Jimenez, MM; Shimizu, T; Keam, B; Meric-Bernstam, F; Rutten, A; Glaspy, J; Schuler, PJ; Parikh, NS; Ising, M; Hassounah, N; Wu, J; Leyk, M; Chen, X; Burks, H; Chaudhury, A; Otero, J; Cabanas, EG.

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Esmo Open. 2024; 9(8): Nº de citas: 3 [doi:10.1016/j.esmoop.2024.103643]

Chatziioannou, E; Higuita, LMS; Kreft, S; Kandolf, L; Dujovic, B; Reinhardt, L; Tamara, E; Marquez-Rodas, I; Fortuna, ARFP; Nübling, A; Niessner, H; Forschner, A; Garbe, C; Popovic, A; Mirjana, B; Meier, F; Eigentler, T; Leiter, U; Flatz, L; Sinnberg, T; Amaral, T.

Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study

Esmo Open. 2024; 9(8): Nº de citas: 2 [doi:10.1016/j.esmoop.2024.103661]

Somoza-Fernández, B; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramírez, S; Villanueva-Bueno, C; Montero-Antón, MD; Herranz-Alonso, A; Sanjurjo-Saez, M.

Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2024; 30(7): 1268-1273 [doi:10.1177/10781552241264530]

Johnston, SRD; Rugo, HS; Tolaney, SM; Fernandez, MM; Wei, R; Martin, M.

Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study

Future Oncology. 2024; 20(28): 2037-2048 [doi:10.1080/14796694.2024.2362095]

Gutiérrez, F; López, L; Carlos, G; Tiraboschi, JM; Portu, J; García-Fraile, L; del Toro, MG; Bernal, E; Rivero, A; García-Abellán, J; Flores, J; González-Cordón, A; Martínez, O; Bravo, J; Rosado, D; Montero, M; Sirera, G; Torralba, M; Galindo, MJ; Macías, J; Gónzalez-Cuello, I; Boix, V; Vivancos, MJ; Dios, P; Blanco, JR; Padilla, S; Fernández-González, M; de la Tabla, AGO; Martínez, E; Masiá, M.

Early Detection of Cancer and Precancerous Lesions in Persons With Human Immunodeficiency Virus (HIV) Through a Comprehensive Cancer Screening Protocol

CLINICAL INFECTIOUS DISEASES. 2024; 80(2): 371-380 Nº de citas: 1 [doi:10.1093/cid/ciae359]

Arija, JAA; del Muro, XG; Caro, RL; Mendez-Vidal, MJ; Perez-Valderrama, B; Aparicio, J; Duran, MAC; Diaz, CC; Duran, I; Gonzalez-Billalabeitia, E.

SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(11): 2783-2799 Nº de citas: 4 [doi:10.1007/s12094-024-03532-2]

Dent, R; André, F; Gonçalves, A; Martin, M; Schmid, P; Schütz, F; Kümmel, S; Swain, SM; Bilici, A; Loirat, D; Valencia, RV; Im, SA; Park, YH; De Laurentis, M; Colleoni, M; Guarneri, V; Bianchini, G; Li, H; Machackova, ZK; Mouta, J; Deurloo, R; Gan, X; Fan, M; Mani, A; Swat, A; Cortés, J.

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

ANNALS OF ONCOLOGY. 2024; 35(7): 630-642 Nº de citas: 21 [doi:10.1016/j.annonc.2024.04.001]

Márquez-Rodas, I; Alvarez, A; Arance, A; Valduvieco, I; Berciano-Guerrero, MA; Delgado, R; Soria, A; Campos, FL; Sánchez, P; Romero, JL; Martin-Liberal, J; Lucas, A; Díaz-Beveridge, R; Conde-Moreno, AJ; de la Gala, MDA; García-Castaño, A; Prada, PJ; Cao, MG; Puertas, E; Vidal, J; Foro, P; de la Rosa, CA; Corona, JA; Cerezuela-Fuentes, P; López, P; Luna, P; Aymar, N; Puértolas, T; Sanagustín, P; Berrocal, A.

Encorafenib and binimetinib followed by radiotherapy for patients with BRAF^V600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)

NEURO-ONCOLOGY. 2024; 26(11): 2074-2083 Nº de citas: 4 [doi:10.1093/neuonc/noae116]

Cerezuela-Fuentes, P; Gonzalez-Cao, M; Puertolas, T; Manzano, JL; Maldonado, C; Yelamos, O; Berciano-Guerrero, MA; Martin-Liberal, J; Muñoz-Couselo, E; Espinosa, E; Drozdowskyj, A; Berrocal, A; Soria, A; Marquez-Rodas, I; Martin-Algarra, S; Quindos, M; Puig, S.

Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 27(1): 386-391 [doi:10.1007/s12094-024-03583-5]

Takashima, A; García-Alfonso, P; Manneh, R; Besen, AA; Hong, YS; Cuyle, PJ; Yanez, P; Burge, M; Yoshino, T; Kim, TW; Cui, K; Li, CX; Jain, R; Adelberg, D; Taieb, J.

Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study

EUROPEAN JOURNAL OF CANCER. 2024; 205: Nº de citas: 5 [doi:10.1016/j.ejca.2024.114036]

López, BH; Cardeña-Gutiérrez, A; Ortiz, AG; López, AG; López, AMG; Alves, AN; Daffós, PR; Sánchez, CAR; Pérez, ARR; Santos, VS; Grau, SS; García, RS; Palmer, MAS.

Exercise in cancer patients: assistance levels and referral pathways-a position statement from the Spanish Society of Medical Oncology

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 27(1): 108-116 Nº de citas: 5 [doi:10.1007/s12094-024-03546-w]

Cánovas, MS; Hernández, MAM; Adoamnei, E; Lavin, DC; Garay, DF; Verdúguez, TQ; Revuelta, JR; Verdejo, FJG; Adrián, SG; Pérez, AIF; García, MEG; Robles, JL; Mendiola, J; Martín, AJM.

Immune checkpoint inhibitors-associated thrombosis in patients with head and neck cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 27(1): 175-181 Nº de citas: 1 [doi:10.1007/s12094-024-03570-w]

Martín, M; Lim, E; Chavez-MacGregor, M; Bardia, A; Wu, J; Zhang, QY; Nowecki, Z; Cruz, FM; Safin, R; Kim, SB; Schem, C; Montero, AJ; Khan, S; Bandyopadhyay, R; Moore, HM; Shivhare, M; Patre, M; Martinalbo, J; Roncoroni, L; Pérez-Moreno, PD; Sohn, J.

Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(18): Nº de citas: 29 [doi:10.1200/JCO.23.01500]

Macarulla, T; Cecchini, M; Garcia-Carbonero, R; Golan, T; Perets, R; Borazanci, EH; Pedregal, M; Ponz-Sarvise, M; Al Hallak, MN; Pant, S; Boni, V; Saavedra, O; de Miguel, MJ; Leal, AD; Martin, AJM; Sauri, T; Schickler, M.

Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer

JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(17_SUPPL): 4143-4143 [doi:10.1200/JCO.2024.42.17_suppl.LBA4143]

Agarwal, N; Castellano, D; Alonso-Gordoa, T; Arija, JAA; Colomba, E; Gravis, G; Mourey, L; Oudard, S; Fléchon, A; González, M; Rey, PM; Schweizer, MT; Gallardo, E; Johnston, E; Balar, A; Haddad, N; Appiah, AK; Nacerddine, K; Piulats, JM.

A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1

CLINICAL CANCER RESEARCH. 2024; 30(11): 2377-2383 Nº de citas: 4 [doi:10.1158/1078-0432.CCR-23-3436]

Marmé, F; Martin, M; Untch, M; Thode, C; Bonnefoi, H; Kim, SB; Bear, H; Mc Carthy, N; Gelmon, K; García-Sáenz, JA; Kelly, CM; Reimer, T; Valota, O; Toi, M; Rugo, HS; Gnant, M; Makris, A; Bassy, M; Zhang, Z; Furlanetto, J; Nekljudova, V; Loibl, S.

Palbociclib combined with endocrine treatment in hormone receptorpositive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B

Esmo Open. 2024; 9(6): Nº de citas: 3 [doi:10.1016/j.esmoop.2024.103466]

Rivas, AS; Alvarez, YE; Cordellat, AB; Tarruella, MM; Mata, KM; Sánchez, MDM; de la Camara, MM; Poves, MZ; Zambrano, CB; Gutierrez, LC.

SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2024; 26(11): 2866-2876 Nº de citas: 4 [doi:10.1007/s12094-024-03502-8]